Kinaset Therapeutics was founded in 2020 through a Series A round by Gimv, 5 AM Ventures and Atlas Ventures. The company is developing a new, innovative and best-in-class treatment for patients with respiratory diseases, with a primary focus on severe asthma. Asthma affects more than 300 million patients worldwide, with about 10% of cases being severe asthma. These patients face various problems such as frequent exacerbations, decreased lung function and reduced quality of life. Gimv’s investment allowed Kinaset to perform a first clinical study, proven its drug is safe and efficacious.